Cancer cachexia research: coming of age.
作者信息
Muqbil Irfana, Azmi Asfar S
机构信息
Lawrence Technological University, Southfield, MI, USA.
Wayne State University School of Medicine, Karmanos Cancer Institute, Detroit, MI, USA.
出版信息
Transl Lung Cancer Res. 2023 Jun 30;12(6):1163-1166. doi: 10.21037/tlcr-23-143. Epub 2023 May 24.
Abstract
摘要
相似文献
1
Cancer cachexia research: coming of age.癌症恶病质研究：走向成熟
Transl Lung Cancer Res. 2023 Jun 30;12(6):1163-1166. doi: 10.21037/tlcr-23-143. Epub 2023 May 24.
2
Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer-chemotherapy toxicity and prognostic value.晚期非小细胞肺癌患者的癌症恶病质、肌肉减少症及生化标志物——化疗毒性与预后价值
Support Care Cancer. 2016 Nov;24(11):4495-502. doi: 10.1007/s00520-016-3287-y. Epub 2016 May 28.
3
Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials).选择性雄激素受体调节剂恩杂鲁胺用于预防和治疗癌症患者肌肉萎缩的3期临床开发项目（POWER试验）的研究设计与原理
Curr Oncol Rep. 2016 Jun;18(6):37. doi: 10.1007/s11912-016-0522-0.
4
The wasting continuum in heart failure: from sarcopenia to cachexia.心力衰竭中的消瘦连续体：从肌肉减少症到恶病质。
Proc Nutr Soc. 2015 Nov;74(4):367-77. doi: 10.1017/S0029665115002438. Epub 2015 Aug 12.
5
Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors.恶病质-肌肉减少症作为非小细胞肺癌患者接受免疫检查点抑制剂治疗的疾病控制率和生存率的决定因素。
Lung Cancer. 2020 May;143:19-26. doi: 10.1016/j.lungcan.2020.03.003. Epub 2020 Mar 5.
6
Ovarian cancer ascites induces skeletal muscle wasting in vitro and reflects sarcopenia in patients.卵巢癌腹水在体外诱导骨骼肌减少，并反映在患者的肌肉减少症中。
J Cachexia Sarcopenia Muscle. 2022 Feb;13(1):311-324. doi: 10.1002/jcsm.12885. Epub 2021 Dec 23.
7
Skeletal muscle wasting after a severe burn is a consequence of cachexia and sarcopenia.严重烧伤后骨骼肌减少是恶病质和肌肉减少症的结果。
JPEN J Parenter Enteral Nutr. 2021 Nov;45(8):1627-1633. doi: 10.1002/jpen.2238. Epub 2021 Sep 2.
8
Comprehensive proteome analysis of human skeletal muscle in cachexia and sarcopenia: a pilot study.恶病质和肌肉减少症患者骨骼肌的综合蛋白质组分析：一项初步研究。
J Cachexia Sarcopenia Muscle. 2017 Aug;8(4):567-582. doi: 10.1002/jcsm.12188. Epub 2017 Mar 15.
9
Exploring the dietary protein intake and skeletal muscle during first-line anti-neoplastic treatment in patients with non-small cell lung cancer.探索非小细胞肺癌患者一线抗肿瘤治疗期间的膳食蛋白质摄入量与骨骼肌情况。
Clin Nutr ESPEN. 2019 Dec;34:94-100. doi: 10.1016/j.clnesp.2019.08.006. Epub 2019 Sep 14.
10
Sarcopenia versus cancer cachexia: the muscle wasting continuum in healthy and diseased aging.肌肉减少症与癌性恶病质：健康和患病衰老中的肌肉消耗连续体。
Biogerontology. 2021 Oct;22(5):459-477. doi: 10.1007/s10522-021-09932-z. Epub 2021 Jul 29.
引用本文的文献
1
Bone mineral density as an individual prognostic biomarker in NSCLC patients treated with immune checkpoint inhibitors.骨密度作为接受免疫检查点抑制剂治疗的非小细胞肺癌患者的个体预后生物标志物。
Front Immunol. 2024 Apr 18;15:1332303. doi: 10.3389/fimmu.2024.1332303. eCollection 2024.
本文引用的文献
1
Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers.转移性非小细胞肺癌的免疫治疗：治疗进展和生物标志物。
Curr Oncol. 2023 Feb 16;30(2):2366-2387. doi: 10.3390/curroncol30020181.
2
The landscape of cancer cachexia in advanced non-small cell lung cancer: a narrative review.晚期非小细胞肺癌中癌症恶病质的概况：一项叙述性综述
Transl Lung Cancer Res. 2023 Jan 31;12(1):168-180. doi: 10.21037/tlcr-22-561. Epub 2023 Jan 16.
3
Role of noncoding RNAs in pancreatic ductal adenocarcinoma associated cachexia.非编码 RNA 在胰腺导管腺癌相关性恶病质中的作用。
Am J Physiol Cell Physiol. 2022 Dec 1;323(6):C1624-C1632. doi: 10.1152/ajpcell.00424.2022. Epub 2022 Oct 24.
4
A preponderance of gastrointestinal cancer patients transition into cachexia syndrome.大量胃肠道癌患者发展为恶病质综合征。
J Cachexia Sarcopenia Muscle. 2022 Dec;13(6):2920-2931. doi: 10.1002/jcsm.13086. Epub 2022 Sep 27.
5
Pancreatic cancer cachexia: three dimensions of a complex syndrome.胰腺癌恶病质：一种复杂综合征的三个维度。
Br J Cancer. 2021 May;124(10):1623-1636. doi: 10.1038/s41416-021-01301-4. Epub 2021 Mar 19.
6
Lung Cancer Cachexia: Can Molecular Understanding Guide Clinical Management?肺癌恶病质：分子层面的认识能否指导临床管理？
Integr Cancer Ther. 2018 Sep;17(3):1000-1008. doi: 10.1177/1534735418781743. Epub 2018 Jun 13.
7
Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome: design, development, and potential place in therapy.盐酸阿那莫林治疗癌症恶病质综合征：设计、研发及在治疗中的潜在地位
Drug Des Devel Ther. 2017 Aug 7;11:2325-2331. doi: 10.2147/DDDT.S110131. eCollection 2017.
8
Cachexia in chronic obstructive pulmonary disease: new insights and therapeutic perspective.慢性阻塞性肺疾病中的恶病质：新见解与治疗前景
J Cachexia Sarcopenia Muscle. 2016 Mar;7(1):5-22. doi: 10.1002/jcsm.12062. Epub 2015 Sep 7.
9
Cachexia and pancreatic cancer: are there treatment options?恶病质与胰腺癌：有治疗选择吗？
World J Gastroenterol. 2014 Jul 28;20(28):9361-73. doi: 10.3748/wjg.v20.i28.9361.
10
Definition and classification of cancer cachexia: an international consensus.癌症恶病质的定义和分类：国际共识。
Lancet Oncol. 2011 May;12(5):489-95. doi: 10.1016/S1470-2045(10)70218-7. Epub 2011 Feb 4.
Zotero 插件